Molecular profile of catabolic versus anabolic treatment regimens of parathyroid hormone (PTH) in rat bone: An analysis by DNA microarray

Journal of Cellular Biochemistry

Volumn 95, Issue 2, 2005, Pages 403-418

  Onyia, Jude E ^a   Helvering, Leah M ^a   Gelbert, Lawrence ^a   Wei, Tao ^a   Huang, Shuguang ^a   Chen, Peining ^a   Dow, Ernst R ^a   Maran, Avudaiappan ^b   Zhang, Minzhi ^b   Lotinun, Sutada ^b   Lin, Xi ^a   Halladay, David L ^a   Miles, Rebecca R ^a   Kulkarni, Nalini H ^a   Ambrose, Emily M ^a   Ma, Yanfei L ^a   Frolik, Charles A ^a   Sato, Masahiko ^a   Bryant, Henry U ^a   Turner, Russell T ^c  

^a ELI LILLY AND COMPANY   (United States)

^b MAYO CLINIC   (United States)

^c OREGON STATE UNIVERSITY   (United States)

Author keywords

Anabolic; BMP3; Bone; Catabolic; Microarray; Neuron specific gene 1; Protein tyrosine phosphatase zeta 1; PTH; Rat

Indexed keywords

DECORIN; MESSENGER RNA; NEURON SPECIFIC ENOLASE; OSTEOCALCIN; OSTEOGENIN; OSTEONECTIN; PARATHYROID HORMONE; PARATHYROID HORMONE[1-34]; PROTEIN TYROSINE PHOSPHATASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BIOMECHANICS; BONE MASS; BONE STRENGTH; CELL DIFFERENTIATION; CONTROLLED STUDY; DNA MICROARRAY; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENETIC REGULATION; MUSCLE STRENGTH; NONHUMAN; NUCLEOTIDE SEQUENCE; OSTEOBLAST; OSTEOPOROSIS; PRIORITY JOURNAL; RAT;

NASA DISCIPLINE REGULATORY PHYSIOLOGY; NON-NASA CENTER;

ANIMALS; BONE AND BONES; FEMALE; GENE EXPRESSION PROFILING; NEURONS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PARATHYROID HORMONE; PEPTIDE FRAGMENTS; RATS;

EID: 23844535637     PISSN: 07302312     EISSN: None     Source Type: Journal    
DOI: 10.1002/jcb.20438     Document Type: Article

References (47)

1. Ashburner M, Ball CA, Blake JA, Botstein D, Butler H, Cherry JM, Davis AP, Dolinski K, Dwight SS, Eppig JT, Harris MA, Hill DP, Issel-Tarver L, Kasarskis A, Lewis S, Matese JC, Richardson JE, Ringwald M, Rubin GM, Sherlock G. 2000. Gene ontology: Tool for the unification of biology. The Gene Ontology Consortium. Nature Genetics 25:25-29.
2. Beck LS, Ammann AJ, Aufdemorte TB, Deguzman L, Xu Y, Lee WP, McFatridge LA, Chen TL. 1991. In vivo induction of bone by recombinant human transforming growth factor beta 1. J Bone Miner Res 6:961-968.
3. Bliziotes MM, Eshleman AJ, Zhang XW, Wiren KM. 2001. Neurotransmitter action in osteoblasts: Expression of a functional system for serotonin receptor activation and reuptake. Bone 29:477-486.
4. Boyle E, Weng S, Gollub J, Jin H, Botstein D, Cherry JM, Sherlock G. 2004. GO::TermFinder - Open source software for accessing gene ontology information and finding significantly enriched gene ontology terms associated with a list of genes. Bioinformatics 20:3710-3715.
5. Burr DB, Hirano T, Turner CH, Hotchkiss C, Brommage R, Hock JM. 2001. Intermittently administered human parathyroid hormone (1-34) treatment increases intracortical bone turnover and porosity without reducing bone strength in the humerus of ovariectomized cynomolgus monkeys. J Bone Miner Res 16:157-165.
6. Calvi LM, Adams GB, Weibrecht KW, Weber JM, Olson DP, Knight MC, Martin RP, Schipani E, Divieti P, Bringhurst FR, Milner LA, Kronenberg HM, Scadden DT. 2003. Osteoblastic cells regulate the haematopoietic stem cell niche. Nature 425:841-846.
7. Centrella M, Horowitz MC, Wozney JM, McCarthy TL. 1994. Transforming growth factor-beta gene family members and bone. Endocr Rev 15:27-39.
8. Chenu C. 2002. Glutamatergic innervation in bone. Microscopy Res Tech 58:70-76.
9. Church GM, Gilbert W. 1984. Genomic sequencing. Proc Natl Acad Sci USA 81:1991-1995.
10. Daluiski A, Engstrand T, Bahamonde ME, Gamer LW, Agius E, Stevenson SL, Cox K, Rosen V, Lyons KM. 2001. Bone morphogenetic protein-3 is a negative regulator of bone density. Nat Genet 27:84-88.
11. Dempster DW, Cosman F, Kurland ES, Zhou H, Nieves J, Woelfert L, Shane E, Plavetic K, Muller R, Bilezikian J, Lindsay R. 2001. Effects of daily treatment with parathyroid hormone on bone microarchitecture and turnover in patients with osteoporosis: A paired biopsy study. J Bone Miner Res 16:1846-1853.
12. Dobnig H, Turner RT. 1995. Evidence that intermittent treatment with parathyroid hormone increases bone formation in adult rats by activation of bone lining cells. Endocrinology 136:3632-3638.
13. Dobnig H, Turner RT. 1997. The effects of programmed administration of human parathyroid hormone fragment (1-34) on bone histomorphometry and serum chemistry in rats. Endocrinology 138:4607-4612.
14. Erlebacher A, Derynck R. 1996. Increased expression of TGF-beta 2 in osteoblasts results in an osteoporosis-like phenotype. Journal of Cell Biology 132:195-210.
15. Faucheux C, Bareille R, Amedee J, Triffitt JT. 1999. Effect of 1,25(OH)2D3 on bone morphogenetic protein-3 mRNA expression. J Cell Biochem 73:11-19.
16. Frolik CA, Black EC, Cain RL, Satterwhite JH, Brown-Augsburger PL, Sato M, Hock JM. 2003. Anabolic and catabolic bone effects of human parathyroid hormone (1-34) are predicted by duration of hormone exposure. Bone 33:372-379.
17. Goss JR, Harley CF, Mata M, O'Malley ME, Goins WF, Hu X, Glorioso JC, Fink DJ. 2002. Herpes vector-mediated expression of proenkephalin reduces bone cancer pain. Ann Neurol 52:662-665.
18. Han B, Perelman N, Tang B, Hall F, Shors EC, Nimni ME. 2002. Collagen-targeted BMP3 fusion proteins arrayed on collagen matrices or porous ceramics impregnated with Type I collagen enhance osteogenesis in a rat cranial defect model. J Orthop Res 20:747-755.
19. Harris MA, Clark J, Ireland A, Lomax J, Ashburner M, Foulger R, Eilbeck K, Lewis S, Marshall B, Mungall C, Richter J, Rubin GM, Blake JA, Bult C, Dolan M, Drabkin H, Eppig JT, Hill DP, Ni L, Ringwald M, Balakrishnan R, Cherry JM, Christie KR, Costanzo MC, Dwight SS, Engel S, Fisk DG, Hirschman JE, Hong EL, Nash RS, Sethuraman A, Theesfeld CL, Botstein D, Dolinski K, Feierbach B, Berardini T, Mundodi S, Rhee SY, Apweiler R, Barrell D, Camon E, Dimmer E, Lee V, Chisholm R, Gaudet P, Kibbe W, Kishore R, Schwarz EM, Sternberg P, Gwinn M, Hannick L, Wortman J, Berriman M, Wood V, de la Cruz N, Tonellato P, Jaiswal P, Seigfried T, White R, Gene Ontology C. 2004. The Gene Ontology (GO) database and informatics resource. Nucleic Acids Res 32:D258-D261.
20. Hock JM, Gera I. 1992. Effects of continuous and intermittent administration and inhibition of resorption on the anabolic response of bone to parathyroid hormone. J Bone Miner Res 7:65-72.
21. Hodges PE, Carrico PM, Hogan JD, O'Neill KE, Owen JJ, Mangan M, Davis BP, Brooks JE, Garrels JI. 2002. Annotating the human proteome: The Human Proteome Survey Database (HumanPSD) and an in-depth target database for G protein-coupled receptors (GPCR-PD) from Incyte Genomics. Nucleic Acids Res 30:137-141.
22. Jaszai J, Farkas L, Gaiter D, Reuss B, Strelau J, Unsicker K, Krieglstein K. 1998. GDNF-related factor persephin is widely distributed throughout the nervous system. J Neurosci Res 53:494-501.
23. Jilka RL, Weinstein RS, Bellido T, Roberson P, Parfitt AM, Manolagas SC. 1999. Increased bone formation by prevention of osteoblast apoptosis with parathyroid hormone. J Clin Investig 104:439-446.
24. Joyce ME, Roberts AB, Sporn MB, Bolander ME. 1990. Transforming growth factor-beta and the initiation of chondrogenesis and osteogenesis in the rat femur. J Cell Biol 110:2195-2207.
25. Kent WJ. 2002. BLAT-The BLAST-like alignment tool. Genome Res 12:656-664.
26. Kloen P, Di Paola M, Borens O, Richmond J, Perino G, Helfet DL, Goumans MJ. 2003. BMP signaling components are expressed in human fracture callus. Bone 33:362-371.
27. Lotinun S, Sibonga JD, Turner RT. 2002. Differential effects of intermittent and continuous administration of parathyroid hormone on bone histomorphometry and gene expression. Endocrine 17:29-36.
28. Ma YL, Cain RL, Halladay DL, Yang X, Zeng Q, Miles RR, Chandrasekhar S, Martin TJ, Onyia JE. 2001. Catabolic effects of continuous human PTH (1-38) in vivo is associated with sustained stimulation of RANKL and inhibition of osteoprotegerin and gene-associated bone formation. Endocrinology 142:4047-4054.
29. Mach DB, Rogers SD, Sabino MC, Luger NM, Schwei MJ, Pomonis JD, Keyser CP, Clohisy DR, Adams DJ, O'Leary P, Mantyh PW. 2002. Origins of skeletal pain: Sensory and sympathetic innervation of the mouse femur. Neuroscience 113:155-166.
30. Marcelli C, Yates AJ, Mundy GR. 1087. In vivo effects of human recombinant transforming growth factor beta on bone turnover in normal mice. J Bone Miner Res 5:1087-1096.
31. Marx SJ. 2000. Hyperparathyroid and hypoparathyroid disorders. N Engl J Med 343:1863-1875.
32. McCauley LK, Koh-Paige AJ, Chen H, Chen C, Ontiveros C, Irwin R, McCabe LR. 2001. Parathyroid hormone stimulates fra-2 expression in osteoblastic cells in vitro and in vivo. Endocrinology 142:1975-1981.
33. McClelland P, Onyia JE, Miles RR, Tu Y, Liang J, Harvey AK, Chandrasekhar S, Hock JM, Bidwell JP. 1998. Intermittent administration of parathyroid hormone (1-34) stimulates matrix metalloproteinase-9 (MMP-9) expression in rat long bone. J Cell Biochem 70:391-401.
34. Miles RR, Sluka JP, Halladay DL, Santerre RF, Hale LV, Bloem L, Thirunavukkarasu K, Galvin RJ, Hock JM, Onyia JE. 2000a. ADAMTS-1: A cellular disintegrin and metalloprotease with thrombospondin motifs is a target for parathyroid hormone in bone. Endocrinology 141:4533-4542.
35. Miles RR, Sluka JP, Santerre RF, Hale LV, Bloem L, Boguslawski G, Thirunavukkarasu K, Hock JM, Onyia JE. 2000b. Dynamic regulation of RGS2 in bone: Potential new insights into parathyroid hormone signaling mechanisms. Endocrinology 141:28-36.
36. Miles RR, Sluka JP, Halladay DL, Santerre RF, Hale LV, Bloem L, Patanjali SR, Galvin RJ, Ma L, Hock JM, Onyia JE. 2002. Parathyroid hormone (hPTH 1-38) stimulates the expression of UBP41, an ubiquitin-specific protease, in bone. J Cell Biochem 85:229-242.
37. Mothe AJ, Brown IR. 2001. Differential mRNA expression of the related extracellular matrix glycoproteins SC1 and SPARC in the rat embryonic nervous system and skeletal structure. Brain Res 892:27-41.
38. Neer RM, Arnaud CD, Zanchetta JR, Prince R, Gaich GA, Reginster JY, Hodsman AB, Eriksen EF, Ish-Shalom S, Genant HK, Wang O, Mitlak BH. 2001. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 344:1434-1441.
39. Onyia JE, Bidwell J, Herring J, Hulman J, Hock JM. 1995. In vivo, human parathyroid hormone fragment (hPTH 1-34) transiently stimulates immediate early response gene expression, but not proliferation, in trabecular bone cells of young rats. Bone 17:479-484.
40. Pollock JH, Blaha MJ, Lavish SA, Stevenson S, Greenfleld EM. 1996. In vivo demonstration that parathyroid hormone and parathyroid hormone-related protein stimulate expression by osteoblasts of interleukin-6 and leukemia inhibitory factor. J Bone Miner Res 11:754-759.
41. Qin L, Qiu P, Wang L, Li X, Swarthout JT, Soteropoulos P, Tolias P, Partridge NC. 2003. Gene expression profiles and transcription factors involved in parathyroid hormone signaling in osteoblasts revealed by microarray and bioinformatics. J Biol Chem 278:19723-19731.
42. Rosen H, Bar-Shavit Z. 1994. Dual role of osteoblastic proenkephalin derived peptides in skeletal tissues. J Cell Biochem 55:334-339.
43. Rubin MR, Bilezikian JP. 2002. The potential of parathyroid hormone as a therapy for osteoporosis. Int J Fertil Womens Med 47:103-115.
44. Schmidt IU, Dobnig H, Turner RT. 1995. Intermittent parathyroid hormone treatment increases osteoblast number, steady state messenger ribonucleic acid levels for osteocalcin, and bone formation in tibial metaphysis of hypophysectomized female rats. Endocrinology 136: 5127-5134.
45. Takeda S, Elefteriou F, Levasseur R, Liu X, Zhao L, Parker KL, Armstrong D, Ducy P, Karsenty G. 2002. Leptin regulates bone formation via the sympathetic nervous system. Cell 111:305-317.
46. Tam CS, Heersche JN, Murray TM, Parsons JA. 1982. Parathyroid hormone stimulates the bone apposition rate independently of its resorptive action: Differential effects of intermittent and continuous administration. Endocrinology 110:506-512.
47. Watson P, Lazowski D, Han V, Fraher L, Steer B, Hodsman A. 1995. Parathyroid hormone restores bone mass and enhances osteoblast insulin-like growth factor I gene expression in ovariectomized rats. Bone 16:357-365.